Yew Bio-Pharm Group, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported total revenues were $15,604,376 against $16,060,110 a year ago. Income from operations was $10,289,748 against $1,308,483 a year ago. Income before provision for income taxes was $10,255,513 against $1,306,345 a year ago. Net income was $10,254,909 against $1,306,345 a year ago. Diluted net income per common share was $0.19 against $0.03 a year ago. Net income increased 685.0% from the same quarter last year due to the decrease in cost of revenues from TCM raw material. For the six months, the company reported total revenues were $23,479,840 against $24,680,479 a year ago. Income from operations was $10,511,325 against $2,386,065 a year ago. Income before provision for income taxes was $10,425,417 against $2,356,607 a year ago. Net income was $10,424,813 against $2,356,607 a year ago. Diluted net income per common share was $0.19 against $0.05 a year ago. Net cash provided by operating activities was $7,635 against $223,795 a year ago. Purchase of intangible assets and yew forest assets of $679,387.